TriRx Pharmaceutical Services acquires MSD Animal Health manufacturing site located in Segré-en Anjou Bleu, France including long-term supply agreement
TriRx Pharmaceutical Services has confirmed the acquisition of a manufacturing site from MSD Sante Animale, part of Merck & Co. (NYSE:MRK), located in Segré, France. This strategic move aims to enhance TriRx's global CDMO presence, ensuring continued supply of veterinary products. The facility, staffed by over ninety employees, is equipped for sterile suspensions and ointments, aligning with TriRx's growth in the animal health market. The agreement includes a long-term supply commitment and has received all necessary regulatory approvals, further positioning TriRx as a leader in contract manufacturing.
- Acquisition enhances global CDMO capacity.
- Continues supply of veterinary products from Segré site.
- Facility expands service offerings into sterile and non-sterile products.
- Over ninety employees contribute to local economy.
- Long-term supply agreement strengthens market position.
- None.
NORWALK, Conn., Sept. 1, 2020 /PRNewswire/ -- TriRx Pharmaceutical Services, a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market, today announced that it has finalized an agreement with MSD Sante Animale, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), to acquire the operations and ownership of their manufacturing site located in Segré, France.
Timothy C. Tyson, Chairman & CEO of TriRx stated, "We are excited to welcome the Segre team to the TriRx family and to partner with MSD Animal Health to continue to provide important products to the market. This transaction allows us to continue our expansion as a global CDMO while assuring continuity of supply of animal health products from the Segré site. The site's history of exceptional performance and the world class knowledge and experience of the site staff expand TriRx service offerings into sterile suspensions and liquids and non-sterile ointments and liquids." The site currently manufactures a range of veterinary products and has over ninety employees.
The state-of-the-art integrated facility has dedicated office, production, sampling and warehouse areas and delivers products to all major global markets. The agreement has officially been executed today with all customary regulatory, regional and local approvals. "This site will transition to a worldwide center of contract manufacturing excellence in the fast growing, animal health market", said Tyson. "And will continue to be a significant contributor to the local economy", Tyson added.
About TriRx
TriRx Pharmaceutical Services is a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market. Headquartered approximately 50 miles outside of New York City in Norwalk, Connecticut, TriRx operates facilities providing state-of-the-art laboratory, manufacturing, packaging and warehousing capabilities. Visit www.trirx.com.
For further information:
Name Jeremy R Tatum, VP Sales
Email jrtatum@trirx.com
Tel 256-714-1839
View original content to download multimedia:http://www.prnewswire.com/news-releases/trirx-pharmaceutical-services-acquires-msd-animal-health-manufacturing-site-located-in-segre-en-anjou-bleu-france-including-long-term-supply-agreement-301120783.html
SOURCE TriRx Pharmaceutical Services
FAQ
What did TriRx Pharmaceutical Services acquire from Merck & Co. (NYSE:MRK)?
How many employees work at the Segré facility acquired by TriRx?
What is the significance of the acquisition for TriRx and Merck & Co. (NYSE:MRK)?
What types of products will the Segré site manufacture post-acquisition?
Is there a long-term supply agreement associated with the TriRx acquisition?
